Dowd, GC,Bahey-el-din, M,Casey, PG,Joyce, SA,Hill, C,Gahan, CGM

2016

May

Human Vaccines & Immunotherapeutics

Listeria monocytogenes mutants defective in gallbladder replication represent safety-enhanced vaccine delivery platforms

Validated

()

biological containment vaccine safety GMO GMM Listeria vaccine LACTOCOCCUS-LACTIS CANCER VACCINES EXPRESSION RESPONSES SYSTEM MODEL LLO

12

2059

2063

The Gram positive intracellular pathogen Listeria monocytogenes represents a promising vaccine or therapeutic DNA delivery vector that has been successfully administered to humans in clinical trials. However in generating Listeria mutants with therapeutic potential it is important to balance safety attenuation with efficacy. Here we show that L. monocytogenes mutants with a reduced capacity for murine gallbladder replication are capable of stimulating T cell responses in mice and protecting vaccinated animals from secondary challenge. Mutation of L. monocytogenes genes lmo2566 or lmo0598 resulted in significant attenuation in the murine model yet mutants retained a capacity for intracellular growth and stimulation of T cell responses against key Listeria epitopes (LLO91-99 and P60(217-225)). Importantly the mutants showed a reduced capacity for growth in the gallbladders of vaccinated mice as well as significantly reduced faecal shedding indicating that this approach generates live Listeria-based vector delivery systems with a reduced capacity for the spread of live genetically modified microorganisms into the natural environment.

10.1080/21645515.2016.1154248